September 21st 2023
Leigh Charvet, PhD, professor of neurology at the NYU Grossman School of Medicine, talked about a trial that aims to address cognitive impairment in patients with long COVID through a unique, remote, and home-based treatment approach.
September 20th 2023
5th Annual International Congress on the Future of Neurology®
Register Now!
Recognizing Rett Syndrome Early to Improve Long-Term Management Outcomes
Register Now!
Shaping the Management of Multiple Sclerosis – The Potential for BTK Inhibitors in Clinical Practice
View More
Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
10/13/2023
Register Now!
From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease
View More
Taking Pompe Disease Management to the Next Level: Optimizing Clinical Assessments and Treatment Decision-Making
View More
Addressing Healthcare Inequities in Stroke Care: How Can We Play an Active Role in Improving Outcomes for All Patients?
View More
2022 4th Annual International Congress on the Future of Neurology
View More
NeuroVoices: Ruth Schneider, MD, on Addressing Psychosis in Lewy Body Diseases
The associate professor in the department of neurology at the University of Rochester provided insight on her presentation on psychosis in Parkinson disease and related disorders given at the 2023 ANA Annual Meeting.
Insights on Potential to Predict Clinical Outcomes in Optic Neuritis
September 19th 2023Hesham Abboud, MD, PhD, associate professor of neurology at Case Western Reserve University School of Medicine, talked about a study that suggested the possibility of predicting the future clinical phenotype of optic neuritis in patients early on.
Building a Greater Understanding of Ulixacaltimide’s Impact in Essential Tremor
Marcio Souza, president and chief executive officer at Praxis Precision Medicines provided follow-up thoughts on recently announced positive findings assessing ulixacaltamide in patients with essential tremor.
Ulotaront Fails to Differentiate From Placebo in Phase 1b Crossover Trial for Narcolepsy-Cataplexy
September 17th 2023Acute and sustained treatment with ulotaront did not show a statistically significant decrease from placebo in total number of cataplexy events and had no significant change in other symptomatic ratings over a 2-week treatment period.
Growing Pains Identified as Early Symptom of Migraine Among Children and Adolescents
September 16th 2023Findings from a recent study showed that pain in the lower limbs of children and adolescents, commonly referred to as growing pains by providers, may reflect a precursor or comorbidity with migraine.
Significant Stroke Risk Disparities Reduced Following Intensive Medical Intervention
September 15th 2023Black adults who had a stroke because of a severe blockage of a major artery in the brain were younger, had higher rates of high blood pressure and type 2 diabetes, and had lower physical activity scores compared with nonBlack adults.
Immunodot Assay Reports High Sensitivity and Specificity for Detecting AQP4-IgG in NMOSD
September 15th 2023In a recent case-control study of 836 human serum samples, including 332 AQP4-IgG–positive and 504 negative samples, the novel immunodot assay showed a 99.4% sensitivity and a 99.2% specificity.
Opioids Improve Disturbed Nocturnal Sleep and Excessive Daytime Sleepiness in Narcolepsy Type 1
September 14th 2023In a recent study on patients with narcolepsy type 1, those who used opioid drugs such as oxycodone and codeine were significantly associated with improved self-reported narcolepsy symptom severity.
Longer Sleep Latency Time Observed With Recent Definition of Sleep Onset, Meta-Analysis Shows
September 14th 2023A recent systematic review and meta-analysis showed that normal mean sleep latency in adults was 11.7 minutes using the earlier definition of sleep onset and 11.8 minutes using the later definition of sleep onset.
Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis
Over a 2-year treatment period, patients on ALZ-801 demonstrated significant correlations between effects on volumetric MRI outcomes and 3 cognitive scales, suggesting cognitive gains are a result of preservation of brain structures from neurodegeneration and atrophy.
Performance of Simulated Real-Life Daily Functioning Test Associated With Risk of Alzheimer Disease
September 13th 2023Findings from a recent exploratory study suggest that assessing daily functioning in a more sensitive way may identify Alzheimer disease before a patient develops more pronounced cognitive changes.